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Abstract 
 
While G-protein coupled receptors (GPCRs) constitute the largest class of membrane proteins, 
structures and endogenous ligands of a large portion of GPCRs remain unknown. Due to the 
involvement of GPCRs in various signaling pathways and physiological roles, the identification of 
endogenous ligands as well as designing novel drugs is of high interest to the research and medical 
communities. Along with highlighting the recent advances in structure-based ligand discovery, 
including docking and molecular dynamics, this article focuses on the latest advances for automating 
the discovery of bioactive ligands using machine learning. Machine learning is centered around the 
development and applications of algorithms that can learn from data automatically. Such an 
approach offers immense opportunities for bioactivity prediction as well as quantitative structure-
activity relationship studies. This review describes the most recent and successful applications of 
machine learning for bioactive ligand discovery, concluding with an outlook on deep learning 
methods that are capable of automatically extracting salient information from structural data as a 
promising future direction for rapid and efficient bioactive ligand discovery. 
  
The final version of this article appeared in Current Opinion in Structural Biology 2019, 55:17–24 
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Introduction 
 
G protein-coupled receptors (GPCRs), an important family of integral membrane proteins, play a 
crucial role in cellular signaling pathways in eukaryotes, and are among the most studied drug 
targets: GPCRs are the targets of approximately 34% of all drugs approved by the US Food and 
Drug Administration [1]. However, based on current estimates, only about 10% of known GPCRs are 
considered to be targeted by drugs for the treatment of a variety of human diseases, including 
hypertension, glaucoma, schizophrenia, and depression [2]. While the exact size of the GPCR family 
is unknown, genome analyses suggest that the GPCR family comprises approximately 800-1000 genes 
in humans [3,4]. More than 150 remain orphan receptors [5], meaning GPCRs for which endogenous 
ligands are still unknown. Since GPCRs are involved in many different cellular and biological 
processes and make excellent drug targets, the prediction and consequent identification of GPCR 
bioactive ligands is a topic of high interest and active research.  
 
GPCR ligands differ in shape, size, and physicochemical properties and include proteins, peptides, 
lipids, steroids, and other small organic molecules [6]. Furthermore, GPCR ligands modulate receptor 
function in complex ways. Ligands exhibit a range of efficacy and can be categorized as full agonists, 
partial agonists, antagonists, or inverse agonists. GPCR ligand chemical diversity and functional 
complexity pose a challenge for discovering novel bioactive ligands and require experimental 
validation beyond what conventional and affordable binding affinity assays can offer. Thus, as a 
cost-effective alternative to wet-lab techniques such as high throughput screening (HTS) for 
identifying putative binding partners for more elaborate bioactivity assays, computational methods 
for ligand discovery have increased in popularity. Aside from being cost-intensive, an often-
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considered downside of HTS is the limited size and diversity of available ligand libraries compared to 
freely available computational libraries, which contain up to hundreds of millions of molecules [7–9]. 
 
Virtual screening has become a major approach for computer-aided ligand discovery and is 
traditionally categorized as either ligand- or structure-based virtual screening. Ligand-based virtual 
screening does not require knowledge of the target structure (i.e., the receptor) and can be 
summarized as a similarity search to known ligands, based on the hypothesis that molecules similar 
to a known binder are also likely to bind the target receptor. Structure-based methods usually 
involve docking a ligand into a receptor’s binding pocket and use a scoring function to rank a library 
of ligands by their predicted affinities. Assessment criteria besides similarity to a known target and 
docking scores of potential ligands include chemical diversity, interaction with key residues, and 
other more general chemical characteristics such as drug likeness [10], not matching any known pan-
assay interference compounds (PAINS) [11], and exhibiting favorable absorption, distribution, 
metabolism, excretion, and toxicity (ADMET) profiles [12]. 
 
The main limitation of molecular docking, which particularly applies to GPCR targets, is the limited 
availability of target structures. While significant advancements in membrane protein X-ray 
crystallography and cryo-electron microscopy have been made in recent years [13,14], available 
GPCR structures only span four out of the six different GPCR classes (A, B, C, F), where structures 
of class A GPCRs (rhodopsin-like receptors) form the largest proportion [15]. Crystal structures of 44 
unique GPCRs are now available, and 205 GPCR structures have been obtained in their ligand-
bound (often inactive, inhibitor-bound) state [1]. While the structures of the seven transmembrane 
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helices are primarily conserved across the six GPCR classes, GPCRs can differ substantially in 
helical deformation and across the intracellular and extracellular loop domains, with the latter, in 
most GPCRs, forming the orthosteric ligand binding site or providing access to ligand binding sites 
that are buried within the transmembrane bundle [16]. The sequence and structural diversity of the 
extracellular loops is related to the diversity of ligand binding sites, which poses challenges for 
compensating the lack of experimental target structures by homology modeling in structure-based 
ligand discovery approaches. In the absence of structural information, non-structure-based 
approaches constitute the only viable alternative [17]. 
 
Machine learning, a field centered around the development and applications of algorithms that can 
learn from data automatically [18], is applicable in both ligand- and structure-based virtual 
screening. The subcategory of supervised machine learning (referred to as machine learning for the 
remainder of this article) focuses on algorithms that learn predictive models from examples. Hence, 
machine learning becomes particularly attractive as activity data becomes available after initial 
rounds of virtual screening and experimental assays, to guide further rounds of screening and 
experimental testing [19]. For instance, machine learning models can be used to predict the activity 
of untested molecules against a target receptor based on the learned relationship between tested 
molecules and their assay values (Figure 1), such as binding affinities, potencies, or binary labels 
(active/inactive) based on a practical threshold.  
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Figure 1. Illustration of a general, supervised machine learning workflow for the automated 
prediction of bioactive ligands of a GPCR. A machine learning algorithm learns a predictive model 
from examples of the inputs (representation of molecules) and outputs (activity data, which can be a 
continuous or categorical variable). Once the model was learned from training examples and 
(molecules associated with activity values) and properly evaluated, the model can be used to predict 
the activity of new molecules. The predicted activity can then be used to prioritize new molecules for 
experimental assays. 
 
Ligand-based virtual screening 
 
As the structure determination of GPCRs is notoriously challenging [20], computational ligand 
discovery has traditionally focused on ligand-based approaches [21–23], which do not require 
knowledge of the structure of the target. Without knowledge about the molecular mechanism of 
interaction, though, molecules identified by ligand-based screening can exhibit agonistic or 
antagonistic properties, which must be determined experimentally. For instance, subtle differences in 
otherwise similar molecules identified by ligand-based virtual screening, such as changing a single 
keto-group of a full agonist into a hydroxyl group, can completely diminish the GPCR-mediated 
signaling response [17]. 
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One of the biggest challenges of traditional ligand-based screening is the definition of a meaningful 
similarity measure [24–26] and the molecular representation, for example, one-dimensional, two-
dimensional [27,28], or three-dimensional fingerprints representing physicochemical and/or structural 
features of the molecules [29] or representation of their complete 2D or 3D structures [30]. Even 
advanced similarity measures that consider volumetric as well as chemical similarity based on three-
dimensional molecular overlays can be uncorrelated with the measured bioactivity of putative GPCR 
ligands [17]. Hence, in the absence of qualitative or quantitative structure-activity relationship 
(QSAR) models, similarity search-based approaches can be severely limited. For instance, in a recent 
benchmark study on 25 bioactivity datasets, researchers found that ligand similarity searching often 
does not perform better than random selection [31]. However, the same study showed that when a 
similarity search is combined with QSAR models, for example, using machine learning methods, the 
discovery rate of bioactive ligands can increase substantially. 
 
Structure-based virtual screening 
 
Structure-based virtual screening for GPCR ligands has become more feasible in recent years due to 
increased structure quality and availability [32]. Since computational capabilities are rapidly 
advancing as well, docking studies are now often accompanied by molecular dynamics simulations, 
which allow more detailed studies of the GPCR-recognition process but remains infeasible large 
ligand libraries [33–36]. However, while the availability of experimental GPCR structures is growing, 
the currently available structures are mostly limited to inactive states. As of now, only a handful of 
atomic resolution GPCR structures are available in their fully active state [20]. This poses a 
challenge for structure-based approaches, as they suffer from a substantially lower performance when 
docking poses are sampled in the presence of non-ligand bound receptor structures [37]. 
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The combination of molecular dynamics and docking can help identify key GPCR-ligand interactions 
on atomistic level [38] for designing pharmacophore models that can be utilized in structure-based, 
ligand-based, and machine learning-based identification of novel bioactive ligands. However, it should 
also be noted that while docking offers the advantage of gaining insights into ligand-receptor 
interactions for further study and ligand design, the ranking of binders according to affinity is often 
inaccurate. These methods are usually only capable of distinguishing between binders and non-
binders [39]. Even in cases where docking leads to correct ranking among GPCR ligands according to 
their activity, the predicted patterns of interaction are often substantially different from the 
interactions found in crystal structures [40] and can be misleading for the further discovery and 
design of highly active ligands. 
 
 
 
Automated bioactive molecule discovery using machine learning 
 
In recent years, machine learning has become one of the most widely used approaches in drug 
discovery and development [31,41–47]. Often, machine learning is combined with structure-based, 
ligand-based, and high-throughput screening to automate QSAR-based target prioritization in 
iterative and automated or semi-automated virtual screening pipelines (Figure 2).  
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Figure 2. Illustration of how and where machine learning could be used to augment the discovery of 
bioactive ligands in a virtual screening pipeline. The gray boxes represent a virtual screening 
workflow that can be either ligand-based (if a bioactive ligand of the target receptor is known), 
structure-based (if the structure of the receptor, including the ligand binding side is known), or a 
combination thereof. The outputs (usually similarity or docking scores) are then used, together with 
domain expertise, to prioritize a set of ligands for experimental assaying from which activity data is 
obtained. Once activity data is available, machine learning algorithms can use these as training 
examples together with one or multiple forms of molecular representations to predict the bioactivity 
of new molecules that have not been tested against the target receptor, yet. 
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In a benchmark study including two GPCR targets, Ericksen et al. found that machine learning 
models trained on an ensemble of docking scores from multiple programs can boost the discovery 
rate of active ligands compared to ranking molecules from a single docking program [48]. Also, in the 
absence of the target GPCR structure, machine learning algorithms have been successfully used to 
discover active ligands based on functional group overlays with a known active from ligand-based 
virtual screening [19]. Furthermore, machine learning can be used to accurately predict target-ligand 
interactions, which was traditionally a task requiring docking and molecular dynamics simulations 
[49]. 
 
Moreover, machine learning offers the opportunity to predict the bioactivity of molecules where 
alternative methods such as docking are inappropriate due to the lack of high-quality experimental 
structures or homology models. Even in the absence of highly active molecules in training datasets, 
machine learning models can accelerate the discovery of highly active compounds, as a recent 
benchmark study based on 25 bioactivity datasets (including four GPCR targets) has shown [31]. 
 
While machine learning can automatically discover complex relationships in high-dimensional 
datasets that escape human interpretation, a common misconception is that machine learning-based 
models are uninterpretable black box models. Several methods exist to connect the predictions of a 
model with chemical features that explain bioactivity. These include model-specific approaches such 
as feature selection based on the weight coefficients of generalized linear models or calculating 
feature importance values in random forests based on information gain maximization as well as 
model-agnostic methods such as feature permutation evaluation [50], and LIME [51], among others. 
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For instance, applying feature selection and random forest algorithms to a dataset of molecular 
overlays of compounds, tested in assays to modulate the biological response of a GPCR involved in a 
pheromone signaling pathway, revealed that the presence of a sulfate group is a key requirement of 
bioactive molecules [19]. As described in their protocol [19], the researchers leveraged the fact that 
machine learning algorithms automatically learn complex relationships between molecular properties 
and experimentally measured bioactivity that maximize the prediction accuracy. The degree to 
which the model relied on the location of functional groups in inhibitor candidates (in relation to a 
known active) to drive the predictions was then used for the automated inference of bioactivity. 
Consequently, the researchers translated the automatically inferred functional group importance to 
filtering criteria for successive rounds of virtual screening, which lead to the discovery of additional 
actives as described in a related manuscript [17].  
 
Machine learning, in particular the application of feature selection algorithms [50] combined with a 
nearest-neighbor classifiers, has also provided strong insights into which segments of GPCRs are 
flexible, independently rigid, or mutually rigid with other regions in active versus inactive GPCRs. 
This analysis by our group was recently carried out on the extracellular and intracellular loops and 
the N-terminal, central, and C-terminal segments of each of the helices in a series of different 
inactive and active GPCR structures. Assessing the flexible versus rigid state in all these segments 
by ProFlex [52] (https://github.com/psa-lab/ProFlex) followed feature importance analysis showed 
that the flexible versus rigid state of six segments alone could predict with high accuracy whether 
the GPCR was in an active or inactive state (96% accuracy for leave-one-out prediction across 27 
GPCRs; Bemister-Buffington, Wolf, Raschka, and Kuhn, manuscript in preparation).  We anticipate 
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that this new method will also be useful for predicting whether designed ligands bound to GPCRs 
will behave as agonist or antagonists, based on the flexibility profile they induce in GPCRs. 
 
Likely owed to the impressive results and state-of-the-art performance on complex tasks such as 
image analysis and language modeling, deep learning, a subfield of machine learning that focuses on 
the training of deep artificial neural networks, has emerged as the most recent trend and promising 
new direction for various molecular modeling tasks including ligand activity prediction and drug 
discovery [41,46,53]. When independent research groups compared different machine learning 
methods on various bioactivity datasets (including two GPCRs, dopamine D4 receptor and 
cannabinoid CB1 receptor), the results indicated that deep neural networks, while requiring more 
extensive tuning [54,55], generally outperform traditional off-the-shelf machine learning algorithms 
such as naïve Bayes classifiers [56–60], logistic regression [19,61–64], support vector machines [65,66], 
and random forests [67–70] when chemical fingerprints were used as input representations 
[54,55,71,72]. Also, one study found that deep neural networks outperform traditional machine 
learning methods on several ChEMBL bioactivity datasets across different molecular descriptors [73]. 
 
Although deep learning is the latest trend in machine learning and biological applications, the 
capacity and overparameterization of deep learning models have a higher tendency to overfit the 
training data and also require more extensive optimization. While machine learning algorithms 
generally benefit from larger dataset sizes [73], deep neural networks can be prone to overfitting in 
scenarios of small training sets and high correlation among the input features [53]. Focusing on 
estrogen receptor binding prediction, researchers found that traditional machine learning methods 
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such as random forest and naïve Bayes are sufficient for predicting bioactive ligands [74,75], which 
may be related to the fact that deep neural network models tend to perform better on larger training 
sets and more complex chemical or physical feature representations [62,76].  
 
 
As deep learning can be considered as a form of representation learning, the next logical step is to 
remove the need for feature engineering and fully automatically derive molecule descriptors that are 
best suited for a given target. For instance, Duvenaud et al. have demonstrated that neural networks 
can automatically learn feature representations that improve upon traditional manual fingerprint 
representations in various molecular prediction tasks [76]. While their study still relied on SMILES 
string inputs (a molecular description that encodes bond connectivity between atoms) to learn the 
molecular representation, graph convolutional neural network were recently used to learn 
representations directly from molecular graphs (where atoms are nodes and bonds are edges) for 
bioactivity prediction [73]. The approach outperformed standard fingerprints and representations 
constructed by chemoinformatics experts on various molecular property prediction tasks [77]. 
 
Conclusions and perspectives 
 
Even though machine learning, and especially the subfield of deep learning, raised skepticism in 
earlier years, companies and academics have now begun to embrace machine learning to further 
advance the automated discovery of drugs and other bioactive ligands [78]. This is partly also owed 
to the availability of free, open-source biological data science [79–81], machine learning, and deep 
learning software libraries [50,82–84], which make these technologies accessible to a wide audience. 
However, while automated methods for inference of bioactive ligands enable these discoveries, care 
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should be taken that models make scientific sense and do not unintentionally exploit experimental 
artifacts [85]. Also, computational inferences do not replace the need for experimental assays for the 
validation and the study of biological effects; they simply enhance the selection of successful 
molecules. When molecules are discovered and prioritized for testing it is also essential to include 
extensive negative controls. For instance, we discovered that hydroxyl groups tend to lead to 
artificially high affinity scores in docking studies [86], resulting in false positives in ligand discovery. 
 
While the recent progress in employing automated methods of inference to bioactive molecule 
discovery is remarkable, the fields of machine learning and deep learning are rapidly advancing as 
well. However, many machine learning methods for bioactive ligand discovery still rely on traditional 
fingerprint representations [55,60] or other molecule descriptors that are being derived manually [54]. 
Currently efforts are also being made to move beyond the analysis of static structures and combine 
molecular dynamics with machine learning for predicting bioactive GPCR ligands and distinguishing 
between antagonists and agonists [87]. However, whether these methods can further be improved by 
considering three-dimensional, non-static representations of molecules remains to be explored.  
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